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1  | INTRODUC TION
As a whole, vascular complications are the leading cause of both the 
early and the late loss of grafts after a liver transplantation. They are 
associated with high rates of retransplantation and related patient 
deaths.1-6 The incidence is higher in children when compared with 
adults. This occurs as a consequence of the unique technical chal-
lenges that are related to smaller caliber vascular anastomosis, and 
the (over)sized mismatched grafts used in infants, as well as with a 
hypoplasia of the PV in children with a biliary atresia.7-14
With the intent of decreasing the incidence of vascular problems 
and graft loss, many pediatric teams have implemented preventive 
and preemptive management strategies during the last decade, in-
cluding our center’s program.15
2  | AIM OF THE STUDY
This research was an observational retrospective study of all chil-
dren (<18 years of age) who benefited from a first isolated liver 
transplantation between November 2008 and December 2015. It 
was a period of time when a multifaceted strategy for the preven-
tion and the early management of vascular complications had been 
prospectively implemented (protocol driven, single center, and single 
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Abstract
Vascular complications are a major cause of patient and graft loss after LTs. The aim 
of this study was to evaluate the effect of a multimodal perioperative strategy aimed 
at reducing the incidence of vascular complications. A total of 126 first isolated LTs—
performed between November 2008 and December 2015—were retrospectively 
analyzed. A minimum follow- up period of 24 months was analyzable for 124/126 
patients (98.4%). The aggressive preemptive strategy consisted of identifying and 
immediately managing any problem and any abnormality in the vascular flow, in any 
of the hepatic vessels, and at any time after the liver graft revascularization. As a re-
sult, with a median follow- up of 57 months (3- 112 months), not a single graft has 
been lost from vascular or biliary problems. The actuarial 8- year graft survival is 
96.5%. These results have shown that a combination of technical attention, medical 
prevention, an early diagnosis, and rapid interventions reduced the negative impact 
of vascular problems on the outcome of both grafts and patients.
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team). The objective of the study was to analyze (a) the incidence 
of vascular complications occurring in the short (<1 month) or late 
(>1 month) term; (b) their management; and (c) the long- term out-
come in terms of graft and patient survival.
3  | MATERIAL S AND METHODS
All of the consecutive first isolated pediatric LTs that were per-
formed at the center between November 1, 2008 (the start of the 
program), and December 31, 2015, were retrospectively analyzed. 
One transplant was excluded because the patient had a prolonged 
cardiac arrest upon reperfusion (cirrhotic cardiopathy) and died 
within 24 hours and was therefore not analyzable for this study. All 
of the other patients were selected for the study, and the minimal 
graft and patient survival was >3 months in all of the cases. The data 
had been previously prospectively collected in the center’s database 
(demographic characteristics, surgical technique, postoperative 
complications, and their management) and with the consent of the 
patients.
As per the protocol, all of the patients had received the same 
induction (anti- interleukin- 2 monoclonal antibodies) and mainte-
nance immunosuppression therapy (intent for tacrolimus monother-
apy—associated with steroids and/or mycophenolate mofetil, when 
required by their clinical needs). In addition, as per the protocol, all of 
the patients were followed perioperatively by implementing a multi-
faceted strategy aimed at reducing the incidence of vascular compli-
cations15-32; this latter strategy was used during the whole period of 
the study and it consisted of 4 main complementary aspects:
3.1 | Flow- optimizing surgical techniques
3.1.1 | Portal vein
The standard technique for a PV anastomosis was an end- to- end 
anastomosis; for all of the left lateral segmental grafts, a triangu-
lar anastomosis was fashioned between the left donor PV and the 
recipient PV bifurcation. In all of the recipients with a PV diameter 
≤5	mm,	a	longitudinal	portal	anterior	venoplasty	was	performed,	by	
using a venous vascular graft from the same donor (an iliac vein from 
the cadaveric donor or an inferior mesenteric vein from the living 
donor).20
3.1.2 | Hepatic artery
All anastomoses were performed using microsurgical techniques, 
and all were performed using 5 times magnification glasses, not 
with a surgical microscope. A separate- stitch suture with Prolene 
8/0	was	the	standard	anastomosis	 for	arteries	≤4	mm	in	diameter,	
while a continuous suture with absorbable material was used for the 
larger ones. As a standard practice, a preference was given to using 
a short length of a donor artery, with a single anastomosis into a 
distal recipient site (proper HA, or right or left branch) (Figure 1)21,22; 
the gastroduodenal artery was kept intact unless a division was nec-
essary for dissecting the PV and for reaching the confluence with 
the splenic and mesenteric veins. When the liver graft was procured 
with multiple arteries, a back- table reconstruction was performed 
in the case of a cadaveric procurement, in order to avoid multiple 
in situ anastomoses; if the graft was from a living donor, the largest 
graft artery was anastomosed first, with the second (smaller) artery 
being reconstructed only when a retrograde pulsatile perfusion was 
absent.
3.1.3 | Inferior vena cava
A large triangular piggyback anastomosis was used as a standard for 
both whole and split grafts.23,24 In order to reduce the risk of twist-
ing or of a kinking of the caval anastomosis, with subsequent outflow 
problems, the small- for- size liver grafts were positioned with care 
and attached to the anterior abdominal wall by using the falciform 
ligament.
3.1.4 | Abdominal wall closure
Attention was given to the closing of the abdomen, so as to pre-
vent a risk of graft compression at the end of the operation. In the 
case of large- for- size grafts, and in any case where the imaging 
by USD suggested compression (reduction in flow at attempting 
closure), abdominoplasty by interposing a prosthesis at the fascia 
level was carried out, before the mobilized skin flaps were closed 
over.25,26
F IGURE  1 Center best practice strategy for a vascular 
reconstruction at the implantation of a left lateral segment: a short 
donor artery (left HA) anastomosed into a distal (right HA) recipient 
by using a microvascular technique and an interrupted suture, a 
preserved (enlarged if necessary) recipient PV trunk (P), a piggyback 
large triangular hepatic vein anastomosis, with an adequate size 
match between the graft volume and the recipient abdomen
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3.2 | Repeated intraoperative Doppler checks
USD was performed during all of the transplant procedures, for at least 
three successive time points: (a) after the arterial reperfusion, (b) at the 
time of the abdominal closure, and (c) after the closure of the abdomen, 
before the patient was transferred back into the ICU. In the case of an 
abnormal Doppler signal (low or absent flow—either in veins or in artery), 
the graft position and the vascular reconstructions were checked (this 
included the possibility of reopening the abdomen immediately after the 
closure), until the problem was solved and until normal Doppler signals 
were obtained.16,19,27-29,32 Blood flow was considered abnormal early 
after reperfusion if PV flow was <15 cm/s, HV flow <10 cm/s, and HA 
systolic maximal velocity <25 cm/s, or HA resistance index >0,8.
3.3 | Perioperative management of the 
coagulation profile
The patient’s coagulation was maintained in a balanced status that 
aimed at avoiding either an excessive coagulopathy (spontaneous or 
iatrogenic) or a thrombophilic condition (which has been shown to be 
naturally occurring in first days/weeks after an LT).18,22,30,33 The objec-
tive was to lower the thrombus formation capacity of the patient, not to 
achieve a fully active anticoagulation; in that perspective, heparin man-
agement was usually not commenced before the second or third day 
after an LT—a period of time when the patient’s INR is usually still >1.5. 
When heparin was started, low doses were used and there was also 
no aim at achieving any given therapeutic range—with in vitro testing—
and it was unusual to see, for example, an aPTT >60 seconds in these 
patients. The aim of this “low anticoagulation” was to avoid a post- LT 
hemorrhage and possible related reinterventions or transfusions.
3.4 | Intraoperative care
The coagulation was checked before and during the procedure, aiming at 
maintaining levels within a range that was lower than normal, but good 
enough to prevent an excessive blood loss during the procedure, as fol-
lows: (a) A slight hypocoagulation state was preferred and this was not 
corrected, while support was given (fresh frozen plasma) if the INR >3; 
and (b) platelets were transfused only in those patients with an active 
hemorrhage refractory to  conventional surgical hemostasis and with 
platelets <50 000/μL. Hemoglobin level was kept between 7 and 9 gr/cL.
By all (surgical) means, the operations were conducted in order 
to reduce the blood loss as much as possible. In those rare patients, 
with a normal coagulation profile before and throughout the proce-
dure (ie, patients with metabolic disease receiving living related liver 
grafts), a low- dose heparin infusion could be started at the end of 
the transplant, if the coagulation results remained fully within the 
normal range at the end of the LT procedure.
For the postoperative course, the following strategy was used:
1. A correction of severe coagulopathy by an infusion of fresh 
frozen plasma in those cases with an early hepatic dysfunction 
and/or with an INR >3.
2. A supplementation of antithrombin in order to maintain the 
plasma level around normal values (target: minimal plasmatic 
value ± 15%).18,22
3. The start of an anticoagulation/antiaggregation protocol, when 
INR was <1.5: 
a. Heparin (5 UI/kg/h intravenous) was started postoperatively 
when an INR was <1.5 and if the platelets were >50 000/dL. 
This therapy was preferred to any other for the first few days, 
because it could be more easily suspended if a reintervention 
is necessary. Heparin was discontinued when the antiaggre-
gant therapy was initiated per os.
b. Aspirin (3 mg/kg/d orally) and dipyridamole (7 mg/kg/d orally) 
therapies were introduced when the patient resumed oral 
nutrition and at the condition that an INR was <1.5 and the 
platelet count was >50 000/dL. Both of these drugs were dis-
continued 3 months after the surgery.
For analyzing the follow- up, the following data were collected:
1. The results of USD: This was performed every day for the 
first 7 days in all of the patients (twice per day in selected 
cases with intraoperative problems or with complex recon-
structions), then twice per week until discharge, and subse-
quently, bimonthly during the first semester.
2. The early graft functions were assessed by analyzing the blood 
test results (ALT, total bilirubin, INR, and platelet count) on PODs 
1, 2, 3, 5, 7, and 15.
3. Vascular complications were defined and categorized as follows: 
absent Doppler signal at USD/established thrombosis at a surgi-
cal revision/absent flow found at a conventional angiography/an 
absence of a contrast enhancement upon a CTA/an abnormal 
Doppler signal during follow-up showing arterial tardus parvus, 
or a low flow (<10 cm/s) in the PV trunk before the 
anastomosis.
4. All of the late outcomes were assessed by the graft and pa-
tient survival rates (actual, 1 and 5 years posttransplant), as 
well as by the results at the last follow-up visit (blood levels of 
ALT, GGT, total bilirubin, and USD). Information about the ac-
tual level of immunosuppression (at the last visit) and the last 
biopsy results (a presence or absence of any signs of ischemic 
or biliary problems and of acute/chronic rejection or chronic 
hepatitis, and the Ishak fibrosis score34) were also collected. 
Lastly, because vascular problems can cause ischemic damage 
and, thereby, secondary biliary problems, information was 
collected about biliary problems in the series, with an atten-
tion focused on their type, their management, and their 
outcome.
Numerical data were expressed by their median values (±SD) and/
or by minimum and maximum. The survival rates were calculated as 
actual rates and then expressed in percentages (n alive/126). Kaplan- 
Meier	analyses	were	used	in	order	to	estimate	the	graft	and	the	pa-
tient’s late survival.
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4  | RESULTS
4.1 | Patient demographics
During the observation period, 126 first isolated LTs were per-
formed. The demographics and the characteristics of the patients 
and the grafts are detailed in Table 1.
4.2 | Vascular reconstructions
4.2.1 | PV reconstruction
PV	hypoplasia	(diameter	≤5	mm)	was	found	in	26/75	biliary	atresia	cases,	
and a longitudinal anterior venoplasty was performed in all of the 26 
cases. One biliary atresia patient benefited from a cavoportal transposi-
tion, in order to manage an unusual malformation of the portal system, 
with an agenesy of the PV. In four patients, a thrombosis of the PV was 
found (two with a portal cavernoma and two with a partial thrombosis 
of the PV trunk). Reconstructions were conducted (a) from the superior 
mesenteric vein and from a large gastric varix in the two patients with 
a cavernoma; (b) by an allograft substitution in a child with a hepato-
blastoma and a PV thrombosis; and (c) by a standard thrombectomy in a 
teenager with primary sclerosing cholangitis and a PV thrombosis.
4.2.2 | HA reconstruction
A single and direct anastomosis was performed in 112 patients 
(88.9%), and a double arterial anastomosis was carried out in 14 
cases (11.1%). In all but one patient, the recipient arterial anastomo-
sis site was the proper or common HA; in a single case, the graft was 
vascularized from the aorta with an aortic conduit (iliac arterial graft 
from the same donor).
4.3 | Intraoperative Doppler US 
findings and management
As described above, an intraoperative Doppler US was performed in 
all of the recipients, (a) after a full graft reperfusion; (b) at a closing of 
the abdominal wall, and (c) before the patient was transferred from 
the theater back into the ICU.
In 114 patients (90.5%), the HA flow was adequate at all of 
the USD checks, intraoperatively, and at follow- up. An immediate 
perioperative USD showed an abnormal arterial flow in 12 cases 
(9.5%) (10 after the reperfusion, one at the closing of the abdomen, 
and one after the closure). The problems were independent of the 
graft type (five full- size, five LRD, two split). In five cases, the flow 
was present, but it was low and the problem was solved by a repo-
sitioning of the graft and a splenic artery ligation; all five patients 
had very large splenomegaly and aged >3,5 years. In five cases, the 
arterial anastomosis was revised with a subsequent correction of 
the flow. In two cases, graft repositioning allowed for a resolution 
of the problem. On leaving the operating room, all of the patients 
had a normal arterial flow at the USD check, but a single one had 
a lower flow in the right HA that normalized within 24 hours under 
a heparin therapy. The USD of these patients has been normal at 
follow- up, in all but one case, who was diagnosed with an arterial 
stricture 2 months later. This was managed successfully by interven-
tional radiology.
The flow in the PV was normal after the reperfusion in 116 
children (92%). Ten patients (8%), of whom eight had a PV hypo-
plasia and longitudinal plasty, had a low PV or an absent flow at 
the USD check. In five cases, the venous anastomosis was revised 
(a full redo in one) and the graft was repositioned in order to avoid 
compression. In four cases, the graft was repositioned, with a pros-
thetic abdominal closure performed in three cases. One patient 
had a normal flow in the PV, but with a low flow in the left branch 
only. This normalized within 24 hours under a heparin therapy. Of 
TABLE  1 Demographic data and characteristics of 126 pediatric 
recipients of a primary isolated liver graft (single- center experience: 
2008- 2015)
Variable types Variable subtypes
N (%) or median ± SD 
(range)
Age (mo) 20.7 ± 56.1 (0.9- 225)
Weight (kg) 10.5 ± 14.7 (2.9- 78.1)
Weight <10 kg (N) 61 (48%)
Indication for 
transplantation
Biliary atresia 75 (59.5%)
Other cholestasis 12 (9.5%)
Fulminant failure 5 (4.0%)
Metabolic	disease 18 (14.3%)
Liver tumors 13 (10.3%)
Other 3 (2.4%)
PELD at transplant 
(score)
Statuses 1 and 2 
excluded
21 ± 3.5
Living donor graft 
only
18 ± 0.7
Postmortem donor 
graft only
22.5 ± 9.9
Donor type Living 38 (30.2%)
Postmortem 88 (69.8%)
Donor/recipient 
weight ratio
5.6 ± 3.6 (0.6- 15.94)
Graft type Whole liver 22 (17.5%)
Extended right lobe 4 (3.2%)
Reduced graft 6 (5.5%)
Left lateral segment 88 (70.6%)
Hyperreduced 
(segment II)
6 (4.0%)
Parenchymal 
division mode
In situ 86
Ex situ 10
Combined in situ/
ex situ
8
Cold ischemic time 
(min)
Postmortem donor 534 ± 109
Living donor 205 ± 91
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the 10 patients with an intraoperative PV problem, all had a normal 
flow at a later follow- up, but one patient who was diagnosed with a 
late thrombosis underwent a successful meso- Rex bypass, 2 years 
after their transplant. No outflow complications were observed in 
this series.
Overall, on the last operative day of the USD check (performed 
before the patient was transferred back into the ICU), the flow in all 
liver vessels was adequate in all of the cases. However, two patients 
who had a minor abnormality (a low flow in their right HA or in their 
left PV) were managed by a heparin infusion.
4.4 | Evolution during the first postoperative 
month and the patient’s management
Six patients had an abnormal arterial flow at their USD check dur-
ing the first month. A splenic artery steal syndrome was diagnosed 
in five patients, typically during the first week (days 1- 4), and 
typically also in five children who had severe and long- standing 
portal hypertension (cirrhotic condition with mean age at trans-
plant = 10 years): Four patients were treated radiologically (proxi-
mal splenic artery embolization) and one was treated by a surgical 
reexploration with a graft repositioning and a ligation of the splenic 
artery.31,35 Another patient was diagnosed during the third week 
with an arterial stricture, and this was treated successfully by a per-
cutaneous angioplasty (POD 17). None of these patients had any 
further problems during their follow- up.
A single patient who was diagnosed with a low PV flow 4 days 
after their transplant had to be explored surgically: A PV anas-
tomosis was redone and the graft was repositioned. This patient 
also required a percutaneous PV balloon venoplasty with stenting, 
4 months later.
The postoperative recovery was otherwise uneventful in the 
majority of patients, and it was characterized by a rapid normaliza-
tion of their liver tests and function (Figure 1). An anticoagulant and 
antiaggregant treatment was administered in all of the patients as 
per the protocol. An antithrombin substitution was started as soon 
as it was necessary after their LTs. However, because the heparin 
treatment was only started when their INR was close to normal, 
many patients initiated their treatment straight away upon their an-
tiaggregant therapy (Figure 2). A heparin anticoagulation treatment 
was used in only 25 children, starting after a median of 4 days after 
their surgery (range 0- 10 days) and for a duration of around 2 weeks 
(median: 14 days, range: 3- 37). All of the recipients received an an-
tiaggregant treatment. Only two patients (1.6%) necessitated a re-
intervention for a hemorrhage within the first month after their LT.
4.5 | Late follow- up, vascular 
complications, and their management
Late vascular complications (>30 days after the LT) were diagnosed 
in 11 patients. They consisted respectively of the following:
1. One late artery thrombosis was diagnosed at POD 70; it was 
clinically silent and recovered with a satisfactory development 
of collateral revascularization; the graft is functioning well and 
is healthy (normal liver tests and function, 6 years after their LT).
2. One HA stricture was managed successfully by radiological inter-
ventional angioplasty at POD 72.
3. PV stenoses in six cases were all managed by radiological inter-
ventional angioplasty (median number of dilatations: 2, range: 
1-5), with two requiring the positioning of a stent. One of the two 
patients with a stent developed a subsequent PV thrombosis, and 
this was cured by a meso-Rex bypass.36 All of the grafts and all the 
patients are doing well.
4. PV thromboses were diagnosed in another three cases (median time 
for diagnosis: 307 days after their LT), including one who had a right 
split graft. Of these three, one was cured by a meso-Rex bypass and 
one is waiting for surgery. The recipient of the right split graft is cur-
rently doing well, with an absence of clinical complications.
5. Lastly, the patient with a PV agenesy and with a malformation of 
the venous abdominal system, who had previously had a portal 
revascularization of the vena cava, benefited from a conversion 
into a meso-Rex bypass after the vascular reassessment and when 
he was over 12 kg of weight (1 year after the LT).
There were no IVC or outflow complications in this series.
F IGURE  2 The results (median values) of coagulation tests (INR 
and platelet count) (above) and of liver function tests (total bilirubin 
and ALT) (below) after 126 pediatric first liver transplantations
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4.6 | Clinical outcomes and graft function
With a median follow- up of 57 months (3- 112 months), the actual 
patient and graft survival rates were 97.6% and 96.8%, respectively 
(Figure 3). Three children died: Two from a recurrence of the disease 
(hemophagocytic lymphohistiocytosis and hepatoblastoma, at three 
and 25 months after their LT, respectively) and 1 other patient from 
a multiresistant bacterial sepsis, at POD 94. Another patient was 
successfully retransplanted for a recurrence of a sclerosing cholan-
gitis (25 months after their first LT).
At their last available checkup, all of the patients had a Doppler 
US which showed a patency of all vascular anastomoses—except for 
one patient with a late HA thrombosis (0.8%) and two patients with 
a thrombosed PV (one is currently waiting for a meso- Rex bypass). 
No graft has been lost due to vascular complications in the series. 
All of the patients who had previously had either a vascular revision, 
an angioplasty, or a meso- Rex bypass have good flows and well- 
functioning grafts.
Overall, there have been six early biliary problems, all of them 
being biliary leaks that were managed successfully by a surgical ex-
ploration, with one of them dealt with by conservative management. 
Another five patients presented late biliary anastomotic strictures—
with none of them having had any previous vascular problems; all 
five were treated by percutaneous radiological interventions with a 
good outcome. Only two patients in the series presented ischemic 
type biliary lesions: In the first patient, who was transplanted in an 
emergency (fulminant hepatitis) with a split graft from a suboptimal 
donor, the cholangiography that was performed a year later showed 
a diffuse biliary damage, typical of a preservation/reperfusion injury, 
but with an absence of vascular problems. In the other patient, a bil-
iary perianastomotic stricture (relatively long and requiring a stent) 
was diagnosed after a late thrombosis of the HA (POD 70); the graft 
recovered well from both of the complications and is currently func-
tioning, 6 years after the LT, while at the same time, it is displaying 
normal liver tests.
Of the whole series, 122 patients are surviving at the long 
term with their first graft. Their liver tests are within the normal 
range in 96 children (78.7%) (at a median follow- up of 59.5 (3- 
110) months); they are within the limit of normal to three times 
the upper normal values in 17 other cases (13.9%) (at a median 
follow- up of 60 (6- 112) months); only eight children have results 
above three times the upper normal limit (6.6%) (at a median 
follow- up of 34.5 (12- 93) months). At the last visit, all of the pa-
tients were receiving immunosuppression as follows: tacrolimus 
in all of them, combined with mycophenolate mofetil in 39 cases, 
or TOR inhibitors in 10 cases.
A liver biopsy was performed at the long term in 120 patients 
(a median time after their LT of 25 months, range: 6- 93 months): 
A graft histology was normal in most of the cases, with 10 having 
features of an acute rejection and 19 patients with signs of some 
chronic inflammation. Fibrosis was scored systematically on the bi-
opsies, according to the Ishak scoring system; in concordance with 
the most recent biopsy for each patient, the score was F0 or F1 in 
89% of those with a follow- up of 2- 5 years and in 75% of the cases 
with a follow- up >5 years after their LT.
5  | DISCUSSION
The ELTR has collected data and outcomes since 1968 and has ac-
cumulated information about 12 239 pediatric liver transplants 
that were performed between 1968 and 2015 (Figure 4). As time 
has passed and liver transplantation has become of age, the results 
have improved and a significant improvement has been observed for 
each period of 5 years, when compared to the previous one, up until 
2000, with P values of 0.003 or lower. Since the year 2000 and for 
the three consecutive periods of 5 years (2000- 2004, 2005- 2009, 
and 2010- 2014) there has been no further improvement and the P 
values in comparing these three periods are 0.14, 0.39, and 0.48, 
respectively (Figure 4): The three latter survival curves are following 
exactly the same pattern over each of the 5 years, suggesting that 
the transplant community has hit a wall. Although it is clear that this 
is multifactorial and that many expert centers have achieved bet-
ter results, at a single- center level, when compared to the median 
multicenter ELTR value, it points to the fact that new strategies or 
therapies are needed in order to progress further as a community.
With a similar starting point, Englesbe et al17—a large group of 
North American transplant centers—have recently contributed to 
an initiative within the SPLIT, developing an innovative methodol-
ogy that has ended by proposing a novel broad- based quality im-
provement proposal. Interestingly, by focusing on the variation in 
outcomes across the transplant centers (a 20% differential in 1- year 
survival), they have concentrated their interest on studying the prac-
tices that are associated with lower incidences of HA thrombosis and 
F IGURE  3 The outcomes of 126 first 
isolated	LTs	(2008-	2015):	Kaplan-	Meier	
test for the survival of patients (upper 
line) and liver grafts (lower line)
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biliary complications—which are considered the main surgical issues. 
Although they have mentioned that quality improvement plans for 
transplantation cannot target only the technical aspects and prob-
lems (as solving only these aspects would not be sufficient to bring 
the median outcome over 95%), they have brought an attention to 
the need for technical refinements, as a road map forward within the 
transplantation community.
Not surprisingly, many centers around the world, including our 
center, have developed independently of the SPLIT initiative, a sur-
gical strategy, and a management approach that are very similar to 
the “best practice report” as proposed by Englesbe et al17 for the 
prevention of HA thrombosis. After their report in 2012, the SPLIT 
group has not reported any further about the success, or the failure, 
of the best practice and of the quality improvement plan. However, 
the results of this series and of others in the literature seem to con-
firm that their approach was adequate and that such a road map 
should be disseminated and practiced with a more standardized 
procedure.
Vascular complications as a leading cause of graft and patient 
loss after an LT have been evidenced in many series, with an in-
cidence of up to 25%.1-6 The incidence is higher in children than 
when compared to adults, very likely due to specific issues, such 
as a low recipient weight, a large donor/recipient mismatch, and 
other anatomical factors, such as a PV hypoplasia.7-13,20 Not sur-
prisingly, by reducing the incidence of these complications, and/
or by minimizing their damaging effects on the graft by an early 
diagnosis and by a rapid adequate management, these actions have 
a major impact on the outcome—not only in the short term, but 
also in the very long term. It is likely that even though a graft may 
tolerate some ischemic damage and survive, the related sequelae 
may occur secondarily and will only become evident with time and 
the limit of the life span of the graft. A late PV thrombosis is a 
good example of an initially well- tolerated problem, but it causes 
extrahepatic portal hypertension that can last for many years with-
out clinical complications; generally, it brings the patient to a very 
difficult condition with exceedingly challenging retransplantation; 
an early meso- Rex bypass has been shown to be a valid option to 
manage these cases.36-38
This cohort of patients has allowed for drawing some robust con-
clusions. The series was large and homogenous, and the follow- up 
was long enough for all of the grafts. Interestingly, more than 80% of 
the liver grafts were technical variants, which is typical of a pediatric 
series but uncommon in many centers. Split grafts procured from 
postmortem donors represented 50% of the transplanted grafts, 
with another 30% of all grafts procured from living donors. The lat-
ter procedure was introduced in the fourth year of the center expe-
rience, at a time when split liver graft offer from optimal donors was 
decreasing in number, with the collateral effects of prolonged wait-
ing time and clinical deterioration of the candidates while waiting for 
the transplant. However, the latter problem was addressed by the 
transplant national authorities in 2015 with a new policy (obligatory 
split) taking effect in late 2015; this augmented dramatically the split 
graft offer (from 32 to 54 split annually): at that time, and by 2016, 
the living program was revisited with a drop of the numbers.
All of the transplants were performed over a relatively short 
time span (7 years) by a single team, using all of the same stan-
dardized operative strategies and techniques, as well as by em-
ploying those stated protocols for both perioperative management 
and immunosuppression. Interestingly, the surgical approaches 
that were applied for these patients were a combination of what 
have been recommended by different teams over the last decade, 
for instance, the use of microsurgical techniques, PV hypoplasia 
corrections, reducing the use of arterial vascular grafts, multiple 
USD checks during and after the LTs, and an early diagnosis and 
a rapid aggressive management for any vascular problem, among 
others.15,16,18-24,28,31,32 With a zero incidence of graft loss related to 
vascular problems and with only two of the 122 currently function-
ing grafts having a non- clinically relevant vascular sequela, it can be 
concluded that the strategy was instrumental in achieving the ex-
cellent outcomes. It was close to a 98% actual patient survival over 
a 7- year period—and with a minimum follow- up of 2 years afterward 
for each graft. These results compare well with other series that 
have been published recently 6,7,39-43 or even earlier.6,44-46	More	
interestingly, these results have suggested that the vast majority 
of surviving grafts have an excellent function at the very long- term 
point, with fully normal liver tests in 78.7% of the patients. At that 
F IGURE  4 The ELTR: pediatric 
patient survival vs the period of liver 
transplantation (1968 - 2016). Global log 
rank P < 0.0001. Log rank P = NS, for 
comparing each of the periods 2000- 
2004, 2005- 2009, and 2010- 2014
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long- term point, with a low fibrosis score (F0 or F1) at biopsy in 
>80% of the whole cohort, this compares well with other series.47 
The latter remarks are forceful elements suggesting that the strat-
egies, comprehensively, have had a protective effect—in fact, more 
than simply targeting at an improved early clinical period.
In this series, all of the vascular flow abnormalities that were 
detected by the USD test during surgery were managed extem-
poraneously: The flows were checked as being normal in all of the 
vessels at the end of the procedure—before the patient was moved 
back into the ICU. The study believes that the latter actions were an 
important aspect of the general strategy and that they were instru-
mental in achieving the good outcomes in this cohort. Postoperative 
vascular complications occurred in 19 cases overall (15%), including 
minor events. They were all successfully cured—with the exception 
of one late HA thrombosis and one late PV thrombosis with a right 
split graft. All of the grafts, excluding the 2 latter ones, are healthy 
and functioning well, with an absence of clinical complications. The 
actual graft survival rate was 96.8%, with 119 of the 122 surviving 
grafts (97.5%) having a vascular anastomosis patency at the USD test.
Few teams have proposed implementing a relatively aggressive an-
ticoagulation protocol after an LT,17,18,22,33 starting very early after the 
graft reperfusion and aiming at higher levels of anticoagulation. This 
study’s data have shown, however, that a full clinical anticoagulation 
status was not necessary to efficiently prevent thrombosis during the 
first weeks after an LT, which may help in reducing the risk of post-
operative bleeding or the need for transfusions or reintervention for 
a hemorrhage. These experiences would suggest that overall, both 
the surgical refinements and the role of radiological follow- up and in-
terventions must be equally emphasized and that an anticoagulation 
therapy has a complementary role, not a solution for all problems.
6  | CONCLUSION
Overall, vascular complications after a pediatric LT are the leading 
cause of graft loss and mortality. An increasing attention has been 
given by many teams in the last decade, in order to prevent and best 
manage these complications, in order to avoid or limit any ischemic 
damage and sequelae. This series has confirmed previous reports 
and other series suggesting that the strategy must be multifaceted. 
Although a zero event incidence may remain difficult to reach, it is 
possible to significantly reduce the related graft loss, both in the 
short term and in the long term. Also, it significantly impacts on pa-
tient survival and the retransplantation rate.
The results highlight that there must be an attention to tech-
nical details at surgery, a balanced anticoagulation therapy to 
avoid the hypercoagulability state, and also an aggressive policy 
of repeated USD tests, combined with a zero tolerance of flow 
abnormalities—thus a preemptive management of vascular flow 
abnormalities after an LT, as well as the timely cure of late vascular 
strictures or thrombosis whenever feasible. Altogether, this seems 
to be an effective and successful strategy in order to limit graft 
and patient loss.
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